ALS Limited (ASX:ALQ)
Australia · Delayed Price · Currency is AUD | Market Cap | 11.29B +30.1% |
| Revenue (ttm) | 3.32B +10.7% |
| Net Income | 318.70M +24.4% |
| EPS | 0.63 +20.0% |
| Shares Out | 507.54M |
| PE Ratio | 35.30 |
| Forward PE | 24.80 |
| Dividend | 0.43 (1.89%) |
| Ex-Dividend Date | Jun 12, 2026 |
| Volume | 207,405 |
| Open | 22.55 |
| Previous Close | 22.24 |
| Day's Range | 22.09 - 22.77 |
| 52-Week Range | 16.65 - 26.17 |
| Beta | 1.15 |
| Analysts | Buy |
| Price Target | 24.07 (+7.87%) |
| Earnings Date | Nov 23, 2026 |
About ALS Limited
ALS Limited engages in the provision of professional technical services and analytical services primarily in the areas of testing, measurement, and inspection in Africa, Asia Pacific, Europe, the Middle East, North Africa, and the United States. It operates in two segments: Commodities and Life Sciences. The Commodities segment offers assaying and analytical testing, and metallurgical services for mining and mineral exploration companies. Its testing and consulting services cover the resource life cycle, including exploration, feasibility, opti... [Read more]
Financial Performance
In fiscal year 2026, ALS Limited's revenue was 3.32 billion, an increase of 10.69% compared to the previous year's 3.00 billion. Earnings were 318.70 million, an increase of 24.40%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ALQ stock is "Buy." The 12-month stock price target is $24.07, which is an increase of 7.87% from the latest price.
News
ALS Limited Earnings Call Transcript: H2 2026
Record FY 2026 results with revenue up 10.7% and NPAT up 25.8%, achieving FY 2027 targets a year early. Strong organic growth in Commodities and Life Sciences, robust cash generation, and disciplined capital allocation support continued investment and margin expansion into FY 2027.
ALS Limited Annual report: H2 2026
ALS Limited has published its H2 2026 annual report on May 17, 2026.
ALS Limited Slides: H2 2026
ALS Limited has posted slides in relation to its H2 2026 quarterly earnings report, which was published on May 17, 2026.
ALS Limited Earnings release: H2 2026
ALS Limited released its H2 2026 earnings on May 17, 2026, summarizing the period's financial results.
ALS Limited Annual report: H2 2026
ALS Limited has published its H2 2026 annual report on May 17, 2026.
ALS Ltd. added to APAC Conviction List at Goldman Sachs
Goldman Sachs analysts added ALS Ltd. (CPBLF) to the firm’s APAC Conviction List as part of its monthly update.
ALS Ltd. upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs upgraded ALS Ltd. (CPBLF) to Buy from Neutral with a A$28 price target The firm says the company’s cyclical leverage should drive continued share price momentum. Published first…
ALS Limited Earnings Call Transcript: H1 2026
Revenue grew 13.3% to AUD 1.7 billion with strong organic and acquisition-driven growth, while underlying EBIT rose 14.7% and NPAT increased 17.2%. Upgraded FY26 organic revenue guidance to 6%-8%, with commodities and life sciences showing robust performance but some regional and segment-specific headwinds.
ALS Limited Quarterly report: H1 2026
ALS Limited has published its H1 2026 quarterly earnings report on November 17, 2025.
ALS Limited Slides: H1 2026
ALS Limited has posted slides in relation to its H1 2026 quarterly earnings report, which was published on November 17, 2025.
ALS Limited Earnings release: H1 2026
ALS Limited released its H1 2026 earnings on November 17, 2025, summarizing the period's financial results.
ALS Limited Transcript: Investor Day 2025
A refreshed strategy focuses on disciplined capital allocation, digital transformation, and targeted growth in minerals and environmental sectors. AI and automation are driving efficiency and margin gains, while a strong M&A pipeline and sustainability commitments support long-term value creation.
ALS Limited Slides: FY 2025
ALS Limited has posted slides in relation to its FY 2025 quarterly earnings report, which was published on July 31, 2025.
ALS Limited Transcript: AGM 2025
FY2025 saw strong revenue growth, robust margins, and significant investment in lab upgrades and digital transformation. The board addressed succession, remuneration, and sustainability, while shareholders engaged on governance, capital raising, and strategic direction. Voting outcomes and future targets were outlined.
ALS Ltd. downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded ALS Ltd. (CPBLF) to Neutral from Buy with a A$17.70 price target The firm cites valuation for the downgrade with the stock now offering 9% upside to…
ALS Ltd. initiated with a Sector Perform at RBC Capital
RBC Capital initiated coverage of ALS Ltd. (CPBLF) with a Sector Perform rating and A$16.75 price target The firm believes regulation – a key driver for Testing, Certification and Inspection…